Cevostamab

DARZALEX (daratumumab), Janssen's CD38-targeting monoclonal antibody, has transformed multiple myeloma treatment across all lines of therapy, generating $11.6 billion in worldwide sales in 2024.

The FDA has accepted Roche's sBLA for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for relapsed/refractory DLBCL patients ineligible for autologous stem cell transplant.

Roche will present over 40 abstracts at the 66th ASH meeting, showcasing advancements in lymphoma and other blood disorders, reinforcing their commitment to hematology.

Roche will present over 40 abstracts at ASH 2024, showcasing advancements in lymphoma treatment with Polivy, Lunsumio, and Columvi, demonstrating its commitment to improving patient outcomes.

Genentech's Polivy, in combination with R-CHP, demonstrates sustained benefits in diffuse large B-cell lymphoma (DLBCL) after five years.